8DECEMBER - JANUARYTHE BROAD AND CURRENT INTEREST OF PHARMACEUTICAL INDUSTRY: CFO'S PERSPECTIVE By Bruno Ruas, CFO, Tecnimede GroupWhen I think about the evolution during my last 16 years as a CFO in the Pharmaceutical Industry and what is to come for the next 5 to 10 years, I enter a whirlwind of questions and uncertainties.Risk, complexity, and unpredictability define the business environment of the next decade. Expectations are high, and changes are disruptive.Buzzwords force us to explore completely new environments that are not yet well known, but they are here to stay. Usually, buzzwords also represent large investments and cash needs. Words like Digitalization, AI, Big Data, Machine Learning, and Biotech are coming like a storm, and we quickly need to adapt/adjust.The role of the CFO is to plan, fund, and control the business while driving financial performance, managing investors' expectations, and ensuring compliance with tax and regulatory requirements.The Big Four Topics in Pharma There are some areas, in addition to the most obvious, which are people and strategy, that, due to the risk they represent, should be analyzed by the CFO together with the board in the long term.In the pharmaceutical industry, I would like to highlight four that are already changing and will continue to change in the coming years. R&DResearch and Development (R&D) is the most critical area for assuring the future of a Pharma Company.Bruno RuasOPINIONIN MY
< Page 7 | Page 9 >